{rfName}
Fa

Indexed in

License and use

Citations

18

Altmetrics

Analysis of institutional authors

Ortiz AAuthor

Share

January 25, 2022
Publications
>
Review
No

Fatty kidney: A possible future for chronic kidney disease research

Publicated to:EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 52 (6): e13748- - 2022-06-01 52(6), DOI: 10.1111/eci.13748

Authors: Kanbay M; Copur S; Demiray A; Sag AA; Covic A; Ortiz A; Tuttle KR

Affiliations

Department of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. - Author
Department of Medicine, Koç University School of Medicine, Istanbul, Turkey. - Author
Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz, Madrid, Spain. - Author
Department of Nephrology, Grigore T. Popa' University of Medicine, Iasi, Romania. - Author
Department of Radiology, Division of Vascular and Interventional Radiology, Duke University Medical Center, Durham, North Carolina, USA. - Author
Division of Nephrology, University of Washington, Seattle, Washington, USA. - Author
Duke Univ, Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, Durham, NC USA - Author
Grigore T Popa Univ Med, Dept Nephrol, Iasi, Romania - Author
IIS Fdn Jimenez Diaz, Madrid, Spain - Author
Koc Univ, Sch Med, Dept Med, Div Nephrol, Istanbul, Turkey - Author
Koc Univ, Sch Med, Dept Med, Istanbul, Turkey - Author
Providence Med Res Ctr, Providence Hlth Care, Spokane, WA USA - Author
Providence Medical Research Center, Providence Health Care, Washington, USA. - Author
Univ Autonoma Madrid, Dept Med, Madrid, Spain - Author
Univ Washington, Div Nephrol, Seattle, WA 98195 USA - Author
See more

Abstract

Metabolic syndrome is a growing twenty first century pandemic associated with multiple clinical comorbidities ranging from cardiovascular diseases, non-alcoholic fatty liver disease, and polycystic ovary syndrome to kidney dysfunction. A novel area of research investigates the concept of fatty kidney in the pathogenesis of chronic kidney disease especially in patients with diabetes mellitus or metabolic syndrome.To review the most updated literature on fatty kidney and provide future research, diagnostic, and therapeutic perspectives on a disease increasingly affecting the contemporary world MATERIALS AND METHOD: We performed an extensive literature search through three databases including Embase (Elsevier) and the Cochrane Central Register of Controlled Trials (Wiley) and Pubmed/Medline Web of Science in November 2021 by using the following terms and their combinations: "fatty kidney", "ectopic fat", "chronic kidney disease", "cardiovascular event", "cardio-metabolic risk", "albuminuria" and "metabolic syndrome". Each study has been individually assessed by the authors.Oxidative stress and inflammation, Klotho deficiency, endoplasmic reticulum stress, mitochondrial dysfunction and disruption of cellular energy balance appear to be the main pathophysiological mechanisms leading to tissue damage following fat accumulation. Despite the lack of large scale comprehensive studies in this novel field of research, current clinical trials demonstrate fatty kidney as an independent risk factor for the development of chronic kidney disease and cardiovascular events.The requirement for future studies investigating the pathophysiology, clinical outcomes and therapeutics of fatty kidney is clear.This article is protected by copyright. All rights reserved.

Keywords

beta-oxidationcd36diabetes mellitusfatty kidneyinsulin-resistanceliver-diseasemetabolic syndromenovel therapyobesityperirenal adipose-tissuerenal lipid-metabolismscavenger receptorsinus fatChronic kidney diseaseDiabetes mellitusFatty kidneyMetabolic syndromeNovel therapyType-2 diabetes-mellitus

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal EUROPEAN JOURNAL OF CLINICAL INVESTIGATION due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 37/169, thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine, General & Internal.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 7.09, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-09, the following number of citations:

  • WoS: 4
  • Scopus: 4
  • Europe PMC: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-09:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 40 (PlumX).

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Oman; Rumanía; Turkey; United States of America.